Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News

July 26, 2007
Norvir/Invirase Go Head-to-Head with Kaletra
Early results from a 48-week clinical trial comparing Norvir (ritonavir)-boosted Invirase (saquinavir) to Kaletra (lopinavir plus ritonavir) suggest that both options are working similarly well in patients starting therapy for the first time, although the rate of virologic failure has thus far been higher in the Norvir/Invirase group. 
Starting or Switching: Truvada Outpaces Combivir in Studies
Researchers have reported extended follow-up data from a clinical trial comparing two pairs of nucleoside reverse transcriptase inhibitors (NRTIs), both combined with Sustiva (efavirenz): once-daily Truvada (tenofovir plus lamivudine) plus Emtriva (emtricitabine) versus Combivir (zidovudine plus lamivudine). 
Is HIV Treatment Actually Reducing Heart Attack Risk?
New study data reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention indicates that HIV treatment—despite its often negative effects on blood lipid levels—may actually reverse artery hardening that can lead to a heart attack or stroke. 
Beyond Condoms: Medical Approaches For Prevention
Regan Hofmann talks with Dr. Nancy Padian about PrEP, microbicides, and circumcision, and asks "when can my boyfriend and I stop using condoms."
July 25, 2007
Sustiva Edges Out Celsentri in Treatment Newbies
A clinical trial has found that Pfizer's CCR5-blocking entry inhibitor, Celsentri (maraviroc), when used by patients starting HIV treatment for the first time, appears somewhat inferior to standard-of-care Sustiva (efavirenz).
Simple Test Can Help Prevent Abacavir Allergy
A clinical trial has confirmed that a simple lab test for a human gene can help prevent a serious allergic reaction caused by abacavir, the active ingredient in Ziagen and a component of Epzicom (Kivexa) and Trizivir. 
High Risk of Kidney Problems in HIV
There is a high rate of kidney problems in HIV-positive patients, according to a French study reported at the fourth IAS Conference on HIV Pathogenesis, Treatment and Prevention, in Sydney.
Pipeline Preview: All The New AIDS Drugs Coming Soon
Peter Staley reviews all the new experimental AIDS drugs with Dr. Joe Eron, including two non-nukes, and two new classes of drugs: CCR5 and integrase inhibitors.
Simple Test Eliminates Abacavir Risk
Peter Staley asks Professor Simon Mallal from the Royal Perth Hospital about a simple new genetic test that accurately predicts if a patient is at risk for an allergic reaction to abacavir (Ziagen).
July 24, 2007
Are We Starting Treatment Early Enough?
In this videocast, Dr. Fred Gordin explains why many experts think we might be waiting too long to put patients on HIV treatment.
Merck’s Isentress Comparable to Sustiva as a First-Time Treatment
Results from an ongoing clinical trial of Isentress (raltegravir) suggest that it has comparable efficacy to Sustiva (efavirenz) after 48 weeks of treatment.
HIV Infection Linked to Higher Skin Cancer Risk
Skin cancer rates are higher among HIV-positive people than among the general population, according to data reported at IAS 2007 in Sydney.
Rilpivirine (TMC-278) Has Metabolic Edge Over Sustiva
Additional side-effect data from a clinical trial of rilpivirine (TMC-278) indicates that it causes minimal changes in lipid (fat) and glucose (sugar) levels over 48 weeks of treatment.
Vicriviroc Shows Benefits, Continues Development
The AIDS Clinical Trials Group has reported additional data from a clinical trial of vicriviroc, Schering-Plough’s experimental entry inhibitor currently in the Phase II stage of development.
A Positive Papua New Guinean Speaks Out Against Stigma
Regan Hofmann interviews Maura Elaripe Mea, the first HIV-positive woman to come forward publicly in her country. Through Igat Hope, the national network of people living with HIV/AIDS in PNG, Maura and others fight AIDS discrimination while spreading information and hope.
The Latest on Lipo: Advances & Setbacks
Dr. Don Kotler discusses the latest from Sydney, both good and bad, on lipodystrophy treatments and cardiovascular risk in people with HIV.
Which HIV Meds Cause Lipoatrophy?
In this videocast, Dr. Eric Daar provides an overview of which nukes, non-nukes, and protease inhibitors might cause fat loss, and which ones probably won't.
July 23, 2007
Crystal Meth Linked to Lower CD4s in Positive People
HIV-positive people using crystal methamphetamine have lower CD4 cell counts than their HIV-positive counterparts who don’t use the drug, according to new data reported at the IAC Conference in Sydney.
Timed Intercourse Plus PrEP for Low-Risk Natural Conception
HIV-negative women who use pre-exposure prophylaxis (PrEP) immediately prior to engaging in carefully timed sexual intercourse with their antiretroviral-treated HIV-positive male partners may further reduce their already low risk of being exposed to the virus.
An Eccentric Professor Expounds on Growing Old With HIV
A videocast interview with Professor Brian Gazzard, an expert on HIV and aging.
July 22, 2007
Celsentri (Maraviroc) Interaction Warning
Based on a recent drug interaction study, Pfizer is warning that the dose of Celsentri (maraviroc) needs to be altered if the drug is combined with Tibotec’s etravirine and/or Prezista.

AIDS Down Under: IAS Conference Begins in Sydney
The IAS Conference on HIV Pathogenesis, Treatment and Prevention began with calls for even greater vigilance to ensure universal access to HIV prevention and treatment, along with an expansion of research to inform and strengthen the global response to HIV.
Fauci Defends Bush's AIDS Legacy
Peter Staley interviews Tony Fauci about his research on HIV "eradication," President Bush's AIDS legacy, why he likes gay men and Republicans, and that letter he wrote supporting Scooter Libby.
July 20, 2007
No Lipodystrophy Approval for Serostim
The Food and Drug Administration (FDA) declined this week to approve EMD Serono’s Serostim for the treatment of HIV-associated adipose redistribution syndrome (HARS)—the accumulation of fat associated with lipodystrophy. As a result, patient access to the drug for HARS will likely be difficult to secure.
July 06, 2007
Prezista/Norvir Bests Kaletra in Treatment-Experienced Patients
Results from a Phase III clinical trial indicate that Prezista (darunavir) plus Norvir (ritonavir) is more effective than Kaletra (lopinavir/ritonavir) in treatment-experienced HIV-positive patients.
Dynamic Duo Etravirine and Prezista Shine in Studies
Data from two ongoing Phase III studies indicate that Tibotec's experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine (TMC-125), combined with their approved protease inhibitor (PI) Prezista (darunavir), packs a powerful antiviral punch in HIV-positive patients with documented NNRTI and PI resistance.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
Read the Blogs
Visit the Forums
African American
Job Listings
Events Calendar

    South Orange County

    Bay Area - Peninsula

    Palm Springs

    el dorado
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Can social media help stop HIV stigma?

Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.